Prolonged Effects of Short-Term Anti-CD20 B Cell Depletion Therapy in Murine Systemic Lupus Erythematosus

被引:85
作者
Bekar, Kai W.
Owen, Teresa
Dunn, Robert [2 ]
Ichikawa, Travis
Wang, Wensheng
Wang, Roger
Barnard, Jennifer
Brady, Sean
Nevarez, Sarah
Goldman, Bruce I.
Kehry, Marilyn [2 ]
Anolik, Jennifer H. [1 ]
机构
[1] Univ Rochester, Med Ctr, Sch Med, Rochester, NY 14642 USA
[2] Biogen Idec Inc, San Diego, CA USA
来源
ARTHRITIS AND RHEUMATISM | 2010年 / 62卷 / 08期
关键词
LYMPHOCYTE DEPLETION; AUTOIMMUNE-DISEASES; MRL/LPR MICE; RITUXIMAB; IMMUNOTHERAPY; ACTIVATION; ARTHRITIS; IMMUNITY; TRIAL; MOUSE;
D O I
10.1002/art.27515
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Although B cells are implicated in the pathogenesis of systemic lupus erythematosus, the role of B cell depletion (BCD) as a treatment is controversial, given the variable benefit in human disease. This study was undertaken to test the effects of BCD therapy in a murine lupus model to better understand the mechanisms, heterogeneity, and effects on disease outcomes. Methods. (NZB x NZW)F-1 female mice with varying degrees of disease severity were treated with an anti-mouse CD20 (anti-mCD20) antibody (IgG2a), BR3-Fc fusion protein (for BAFF blockade), or control anti-human CD20 monoclonal antibody (similar to 10 mg/kg each). Tissue samples were harvested and analyzed by flow cytometry. The development and extent of nephritis were assessed by monitoring proteinuria (using a urine dipstick) and by immunohistochemical analysis of the kidneys. Serum immunoglobulin levels were measured by enzyme-linked immunosorbent assay. Results. After a single injection of anti-mCD20, BCD was more efficient in the peripheral blood, lymph nodes, and spleen compared with the bone marrow and peritoneum of normal mice as well as younger mice with lupus. Since depletion of the marginal zone and peritoneal B cells was incomplete and variable, particularly in older mice with established nephritis, a strategy of sequential weekly dosing was subsequently used, which improved the extent of depletion. BAFF blockade further enhanced depletion in the spleen and lymph nodes. Early BCD therapy delayed disease onset, whereas BCD therapy in mice with advanced disease reduced the progression of nephritis. These effects were long-lasting, even after B cell reconstitution occurred, and were associated with a reduction in T cell activation but no significant change in autoantibody production. Conclusion. The lasting benefit of a short course of BCD therapy in lupus-prone mice with an intact immune system and established disease highlights the validity of this treatment approach.
引用
收藏
页码:2443 / 2457
页数:15
相关论文
共 50 条
  • [21] B-lymphocyte depletion ameliorates Sjogren's syndrome in Id3 knockout mice
    Hayakawa, Ikuko
    Tedder, Thomas F.
    Zhuang, Yuan
    [J]. IMMUNOLOGY, 2007, 122 (01) : 73 - 79
  • [22] Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
    Hu, Chang-Yun
    Rodriguez-Pinto, Daniel
    Du, Wei
    Ahuja, Anupama
    Henegariu, Octavian
    Wong, F. Susan
    Shlornchik, Mark J.
    Wen, Li
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) : 3857 - 3867
  • [23] Treating patients with lupus with B-cell depletion
    Isenberg, D. A.
    [J]. LUPUS, 2008, 17 (05) : 400 - 404
  • [24] Effective B cell depletion with rituximab in the treatment of autoimmune diseases
    Kneitz, C
    Wilhelm, M
    Tony, HP
    [J]. IMMUNOBIOLOGY, 2002, 206 (05) : 519 - 527
  • [25] An open study of B lymphocyte depletion in systemic lupus erythematosus
    Leandro, MJ
    Edwards, JC
    Cambridge, G
    Ehrenstein, MR
    Isenberg, DA
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (10): : 2673 - 2677
  • [26] TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production
    Lenert, P
    Brummel, R
    Field, EH
    Ashman, RF
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2005, 25 (01) : 29 - 40
  • [27] B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice
    Li, Yongmei
    Chen, Fangqi
    Putt, Mary
    Koo, Yumee K.
    Madaio, Michael
    Cambier, John C.
    Cohen, Philip L.
    Eisenberg, Robert A.
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 181 (05) : 2961 - 2972
  • [28] B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
    Looney, RJ
    Anolik, JH
    Campbell, D
    Felgar, RE
    Young, F
    Arend, LJ
    Sloand, JA
    Rosenblatt, J
    Sanz, I
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (08): : 2580 - 2589
  • [29] Cytokine-producing B lymphocytes - key regulators of immunity
    Lund, Frances E.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (03) : 332 - 338
  • [30] Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations
    Mackay, F
    Woodcock, SA
    Lawton, P
    Ambrose, C
    Baetscher, M
    Schneider, P
    Tschopp, J
    Browning, JL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (11) : 1697 - 1710